ALFA FinderBSE filing, NSE: BHARATFORG. Summary written from the filing by ALFA Finder's alert engine.
Bharat Forge Ltd: key numbers
- Share price
- ₹1,759.90
- Market cap
- ₹86,001 Cr
- Revenue (annual)
- ₹16,812 Cr
- Net profit (annual)
- ₹1,080 Cr
- P/E (TTM)
- 120.9×Sector 51.9×
- Promoter holding
- 43.12%-0.95% QoQ
- FII holding
- 15.20%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Bharat Forge Ltd
All →Bharat Forge Earnings Call Transcript: Key Takeaways
Record standalone revenue ₹2,526 Cr (+30% YoY), but consolidated EBITDA up only 9%. US loss-making, Europe at 3% margin; H2 recovery hinges on cost pass-through.
Bharat Forge Other Announcement
Bharat Forge filed CARE Ratings' monitoring agency report on its ₹2,000 Crore QIP proceeds for the quarter ended September 30, 2026. The report notes nil deviation from the stated objects.
Bharat Forge Legal & Regulatory
Bharat Forge's board noted a ₹10,000 NSE fine for delayed XBRL filing of postal ballot voting results. The company sought a waiver, which the board endorsed.
- Value
- ₹0.00 Cr
Bharat Forge Capital Structure Change
Bharat Forge Limited has approved a cash investment of Rs. 290.51 Crore in its wholly-owned subsidiary, Kalyani Strategic Systems Limited. The funds will support capital expenditure and product development in the defense sector.
- Value
- ₹290.5 Cr
- Execution
- By March 31, 2027
Bharat Forge Investor Presentation: Key Takeaways
Q2 FY27 consolidated revenue Rs 48,700m (+20.8% YoY), EBITDA Rs 7,780m (16.0% margin), standalone PAT Rs 3,708m (+19.6% YoY). Indian manufacturing growth guidance maintained; overseas under strategic review.
Bharat Forge Q2 FY27 Results: Net Profit ₹278.7 Cr, Down 6.9% YoY
Bharat Forge Ltd reported revenue from operations of ₹4,870 Cr (+20.8% YoY) and net profit of ₹278.7 Cr (-6.9% YoY) for Q2 FY27.
- Key figure
- Net profit ₹278.7 Cr · -6.9% YoY
Other product launch announcements
All →Lupin Product Launch
Lupin announced the European launch of its biosimilar Ranibizumab (Ranluspec) via commercial partner Sandoz. The launch covers Europe excluding Germany following European Commission approval.
LTM Product Launch
LTM publishes AI-QEM, its Quantum Error Mitigation tool, in IBM's Quantum Functions Catalog, becoming the first global systems integrator to do so.
Jeena Sikho Lifecare Product Launch
Jeena Sikho Lifecare launched ten new Ayurvedic healthcare products in the domestic market on November 11, 2026. The filing gives product-wise details under SEBI product-launch disclosure rules.
HCL Technologies Product Launch
HCLTech launched a pre-configured semiconductor PLM solution built on PTC Windchill, developed in collaboration with PTC. The release states no contract value or deal size, and the launch is a new product offering.
Morepen Laboratories Product Launch
Morepen launched Desloratadine Tablets USP 5 mg, its first US prescription generic, through subsidiary Morepen Bio Inc. It also filed a Sitagliptin ANDA with the US FDA.
AstraZeneca Pharma India Product Launch
AstraZeneca Pharma India will launch Datverzo, Datopotamab Deruxtecan, in India in November 2026. The drug holds DCGI import and market permission for HR-positive, HER2-negative breast cancer.